دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Rituximab Versus Mycophenolate in the Treatment of Recalcitrant Connective Tissue Disease–Associated Interstitial Lung Disease
Lisa Zhu, 1 Melody P. Chung, 1 Laurence Gagne, 2 Haiwei H. Guo, 1 Zachary Guenther, 3 Shufeng Li, 1 Susan Jacobs, 1 Julie Morisset, 2 Joshua J. Mooney, 1 Rishi Raj, 1 and Lorinda Chungcorresponding author 1
doi : 10.1002/acr2.11210
ACR Open Rheumatol. 2021 Jan; 3(1): 3–7.
Interstitial lung disease (ILD) is a major cause of morbidity and mortality in connective tissue diseases (CTDs). We aimed to assess the effect of rituximab ± mycophenolate mofetil (MMF) compared with MMF on pulmonary function and prednisone dosage in patients with CTD?related ILD (CTD?ILD).
Racial Disparities in Systemic Sclerosis: Short? and Long?Term Outcomes Among African American Participants of SLS I and II
Elizabeth R. Volkmann,corresponding author 1 Virginia Steen, 2 Ning Li, 1 Michael D. Roth, 1 Philip J. Clements, 1 Daniel E. Furst, 1 Shervin Assassi, 3 Dinesh Khanna, 4 Grace?Hyun J. Kim, 1 Jonathan Goldin, 1 Robert M. Elashoff, 1 , † and Donald P. Tashkin 1
doi : 10.1002/acr2.11206
ACR Open Rheumatol. 2021 Jan; 3(1): 8–16
To evaluate short? and long?term outcomes of African American (AA) participants of Scleroderma Lung Studies (SLS) I and II.
Effects of the COVID?19 Pandemic on Patients Living With Vasculitis
Shubhasree Banerjee,corresponding author 1 Michael George, 1 Kalen Young, 2 Shilpa Venkatachalam, 3 Jennifer Gordon, 4 Cristina Burroughs, 5 David Curtis, 3 Marcela Ferrada, 6 Kelly Gavigan, 3 Peter C. Grayson, 6 Joyce Kullman, 2 Maria I. Danila, 7 Jeffrey R. Curtis, 7 Dianne G. Shaw, 2 W. Benjamin Nowell, 3 Peter A. Merkel, 1 and the Vasculitis Patient?Powered Research Network
doi : 10.1002/acr2.11204
ACR Open Rheumatol. 2021 Jan; 3(1): 17–24
This study aimed to analyze the concerns and health?related behaviors in patients with vasculitis during the early phase of the coronavirus disease 2019 (COVID?19) pandemic in North America.
Development and Evaluation of a Clinic for Elderly Patients with Rheumatoid Arthritis and Multimorbidity: A Pilot Study
Anne van Moerbeke, 1 Fabienne Magdelijns, 1 Fiona Cleutjens, 2 Annelies Boonen, 1 and Marloes van Onnacorresponding author 1
doi : 10.1002/acr2.11213
ACR Open Rheumatol. 2021 Jan; 3(1): 34–40
Integrating patient’s and physician’s goals, especially in elderly patients with multimorbidity, might ultimately improve care. Efforts to develop such care innovations in patients with rheumatoid arthritis (RA) are lacking. The objective of our study was to develop and to pilot test a clinic for elderly patients with RA and multimorbidity.
Role of Serum IL?6 in Neuropsychiatric Systemic lupus Erythematosus
Shunsei Hirohatacorresponding author 1 and Hirotoshi Kikuchi 2
doi : 10.1002/acr2.11217
ACR Open Rheumatol. 2021 Jan; 3(1): 42–49
The present study was designed in order to elucidate the roles of serum interleukin 6 (IL?6) in the pathogenesis in neuropsychiatric systemic lupus erythematosus (NPSLE).
Improving Knowledge of Lactation Compatibility of Antirheumatic Medications Among Providers Who Care for Patients With Rheumatic Disease
Brooke S. Millscorresponding author 1 and Bonnie L. Bermas 1
doi : 10.1002/acr2.11214
ACR Open Rheumatol. 2021 Jan; 3(1): 50–54
We sought to evaluate and improve knowledge of lactation compatibility of medications commonly used to treat rheumatic diseases among rheumatology, obstetric, and newborn providers practicing at an academic safety net hospital.
Exploring Beliefs and Preferences for Reducing Sedentary Behavior Among Adults With Symptomatic Knee Osteoarthritis or Knee Replacement
Sara M. Powell, 1 Chelsea A. Larsen, 2 Siobhan M. Phillips, 3 and Christine A. Pellegrinicorresponding author 2
doi : 10.1002/acr2.11216
ACR Open Rheumatol. 2021 Jan; 3(1): 55–62
Physical activity has numerous benefits for those with symptomatic knee osteoarthritis (KOA) or knee replacement, yet many individuals engage in insufficient activity. The purpose of this study was to explore beliefs about sedentary behavior, barriers to standing, and program preferences for adults with symptomatic KOA or knee replacement.
Exploring the Mental Health Needs of Persons With Autoimmune Diseases During the Coronavirus Disease 2019 Pandemic: A Proposed Framework for Future Research and Clinical Care
Kathleen S. Bingham,corresponding author 1 Nathalie Rozenbojm, 2 Mariah Chong?East, 3 and Zahi Touma 4
doi : 10.1002/acr2.11205
ACR Open Rheumatol. 2021 Jan; 3(1): 25–33
Although the coronavirus disease 2019 (COVID?19) pandemic has been associated with increased psychological distress globally, it poses unique challenges to persons who are potentially more vulnerable to its effects, including patients with autoimmune disease. In this article, we review the published literature and media reports to determine factors that may contribute to mental health challenges in persons with autoimmune disease. We then explore existing mental health interventions that have been developed for use in COVID?19 and in patients with autoimmune disorders in general. We identified several potential contributors to psychological distress in patients with autoimmune disease during the pandemic, as follows: feelings of discrimination related to societal response to COVID?19, fear of infection and uncertainty related to immunosuppressive medication, diminished access to usual care and resources, previous health?related trauma, and the exacerbating effect of social isolation. Drawing from existing literature, we synthesize the identified evidence to develop a proposed framework for researching and managing mental health challenges in autoimmune disease during the pandemic and its aftermath.
Clinical Images: Hydroxychloroquine?associated mucous labial pigmentation in a patient with systemic lupus erythematosus improving under topical treatment with tacrolimus
Ian Pirker,corresponding author 1 Ieva Saulite, 1 and Johannes von Kempis 1
doi : 10.1002/acr2.11209
ACR Open Rheumatol. 2021 Jan; 3(1): 41
